MacroGenics is axing the development of one of its antibody-drug conjugates (ADC) after it flopped in a Phase II study in prostate cancer.
MacroGenics has made the final decision to abandon work on one of its more advanced antibody-drug conjugates after taking a look at the latest phase 2 data.
MacroGenics has pumped the brakes on vobramitamab duocarmazine (vobra duo), pausing investment in additional opportunities for the antibody-drug conjugate (ADC) until it has updated data from a phase 2 monotherapy prostate cancer trial.
MacroGenics’ stock dropped by as much as 70% Friday morning after the biotech disclosed five deaths in the Phase II TAMARACK trial for its investigational antibody-drug conjugate vobramitamab duocarmazine in metastatic castration-resistant prostate cancer.
AbbVie has cut short its call on the ADAM family. The ADAM9-targeted antibody-drug conjugate (ADC) IMGC936 fell short of safety and efficacy expectations in solid tumors, prompting AbbVie and its equal partner MacroGenics to walk away from the candidate.
DRI Healthcare Trust, a prolific acquirer of drug royalties, is paying $100 million for a piece of a first-of-its-kind Type 1 diabetes drug.
In an announcement Thursday, DRI said it bought royalties to the medicine, called Tzield and designed to delay the onset of Type 1 diabetes, from biotechnology company Macrogenics. The FDA approved Tzield last November for individuals over the age of 8 who are considered to be in Stage 2, or “at risk,” of the autoimmune disease.
Gilead Sciences and MacroGenics entered into a licensing and collaboration pact worth up to $1.7 billion to develop a bispecific antibody to treat hematological cancers. This comes only two months after the latter announced staff cuts.
MacroGenics has closed a phase 2 clinical trial of its anti-cancer antibody enoblituzumab after learning of seven deaths potentially associated with hemorrhagic events. The setback means two of MacroGenics’ three attacks on the protein B7-H3 have hit setbacks, but the biotech is forging ahead with the third candidate.
Cancer player MacroGenics scored a big win with its full approval for anti-HER2 drug Margenza last winter based on a head-to-head matchup with breast cancer titan Herceptin. Now, a fuller look at Margenza’s survival data months after that approval could spell a rough road ahead for the drug.
After yesterday’s advisory panel setkback Macrogenics/Incyte’s retifanlimab looks unlikely to become the eighth anti-PD-(L)1 MAb to get US approval. This is despite being filed in squamous carcinoma of the anal canal, a niche indication with no approved checkpoint blockers.